SCEMBLIX 40 mg, film-coated tablets 60 tablets
Active ingredients: Asciminib, Asciminib hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SCEMBLIX 40 mg, comprimés pelliculés
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) polychlortrifluoroéthylène PVC aluminium de 60 comprimés
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 29 Nov 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65990614CIP73025812CIP133400930258125Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE D'ASCIMINIBcomprimé | — | SA |
| ASCIMINIBcomprimé | 40 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.